Iraq's National Drug System requires comprehensive registration of all pharmaceutical products and manufacturers within its centralized digital platform. This encompasses both locally produced medications and imported pharmaceuticals, ensuring that every product entering the Iraqi market is properly documented and tracked from point of entry to end-user consumption. The system maintains detailed records of all licensed manufacturers, both national and international, creating a complete database that supports regulatory decision-making and market surveillance activities.

Each pharmaceutical product must display a specially designed electronic label featuring essential drug information, official pricing, and a unique QR code for instant verification. This labeling system transforms how consumers and healthcare professionals interact with medications, providing immediate access to critical product data including drug names, expiry dates, manufacturer details, active ingredients, side effects, warnings, and precautions. The QR code functionality serves as a powerful anti-counterfeiting measure while empowering consumers to make informed decisions about their medications.

The system includes a dedicated mobile application that enables citizens to verify medication authenticity and safety by simply scanning the QR code. This consumer-facing technology provides instant access to comprehensive product information, creating transparency that builds public trust in the pharmaceutical supply chain. Healthcare professionals can also leverage this verification system to ensure they are dispensing authentic medications, while regulatory authorities gain real-time visibility into product distribution patterns and potential safety concerns.

Iraq's National Drug System provides regulatory authorities with sophisticated data analytics capabilities that support enhanced market surveillance, inspection planning, and rapid response to safety issues. The platform generates detailed statistics and insights that inform national drug security policies and enable proactive regulatory interventions. This data-driven approach allows authorities to identify trends, detect anomalies, and maintain robust oversight of the pharmaceutical market while supporting evidence-based policy development.